271.39
1.56 (0.58%)
| Penutupan Terdahulu | 269.83 |
| Buka | 265.40 |
| Jumlah Dagangan | 1,004,153 |
| Purata Dagangan (3B) | 1,537,277 |
| Modal Pasaran | 38,867,222,528 |
| Harga / Jualan (P/S) | 14.50 |
| Harga / Buku (P/B) | 21.15 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 6 Aug 2026 |
| Margin Keuntungan | -10.36% |
| Margin Operasi (TTM) | -15.78% |
| EPS Cair (TTM) | -1.47 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 36.50% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 15.78% |
| Nisbah Semasa (MRQ) | 3.87 |
| Aliran Tunai Operasi (OCF TTM) | 153.12 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 120.93 M |
| Pulangan Atas Aset (ROA TTM) | -8.87% |
| Pulangan Atas Ekuiti (ROE TTM) | -18.66% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Diagnostics & Research (US) | Bercampur | Menaik |
| Diagnostics & Research (Global) | Bercampur | Menaik | |
| Stok | Natera, Inc. | Bercampur | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | -2.5 |
| Volatiliti Harga | -0.5 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | 2.5 |
| Purata | 0.50 |
|
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection. |
|
| Sektor | Healthcare |
| Industri | Diagnostics & Research |
| Gaya Pelaburan | Mid Growth |
| % Dimiliki oleh Orang Dalam | 3.24% |
| % Dimiliki oleh Institusi | 96.37% |
Tiada data dalam julat masa ini.
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| CHAPMAN ROWAN E | - | 277.37 | -135 | -37,445 |
| SHEENA JONATHAN | - | 275.13 | -4,650 | -1,275,659 |
| Jumlah Keseluruhan Kuantiti Bersih | -4,785 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | -1,313,103 | |||
| Purata Pembelian Keseluruhan ($) | - | |||
| Purata Jualan Keseluruhan ($) | 275.88 | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| SHEENA JONATHAN | Pengarah | 15 Jul 2026 | Jual automatik (-) | 1,500 | 277.37 | 416,055 |
| CHAPMAN ROWAN E | Pengarah | 15 Jul 2026 | Jual automatik (-) | 135 | 277.37 | 37,445 |
| SHEENA JONATHAN | Pengarah | 13 Jul 2026 | Jual automatik (-) | 3,150 | 272.89 | 859,604 |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |